These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 508017)

  • 1. Prolactinomas. Our raised consciousness.
    Moore TJ
    Arch Intern Med; 1979 Nov; 139(11):1223-4. PubMed ID: 508017
    [No Abstract]   [Full Text] [Related]  

  • 2. Physiologic concentrations of dopamine fail to suppress prolactin secretion in patients with idiopathic hyperprolactinemia or prolactinomas.
    Tallo D; Malarkey WB
    Am J Obstet Gynecol; 1985 Mar; 151(5):651-5. PubMed ID: 3976764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolactinomas in women: current therapies.
    Robinson AG; Nelson PB
    Ann Intern Med; 1983 Jul; 99(1):115-8. PubMed ID: 6344716
    [No Abstract]   [Full Text] [Related]  

  • 4. Prolactinomas.
    Grossman A; Besser GM
    Br Med J (Clin Res Ed); 1985 Jan; 290(6463):182-4. PubMed ID: 3917745
    [No Abstract]   [Full Text] [Related]  

  • 5. Long term suppression of prolactin concentrations after bromocriptine induced regression of pituitary prolactinomas.
    Hancock KW; Scott JS; Lamb JT; Gibson RM; Chapman C
    Br Med J (Clin Res Ed); 1985 Jan; 290(6462):117-8. PubMed ID: 3917709
    [No Abstract]   [Full Text] [Related]  

  • 6. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas.
    Luque GM; Perez-Millán MI; Ornstein AM; Cristina C; Becu-Villalobos D
    J Pharmacol Exp Ther; 2011 Jun; 337(3):766-74. PubMed ID: 21406548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interpreting prolactin levels: implications for the management of large pituitary lesions.
    Bevan JS
    Br J Neurosurg; 1991; 5(1):3-6. PubMed ID: 2021431
    [No Abstract]   [Full Text] [Related]  

  • 8. Update on prolactinomas. Part 1: Clinical manifestations and diagnostic challenges.
    Wong A; Eloy JA; Couldwell WT; Liu JK
    J Clin Neurosci; 2015 Oct; 22(10):1562-7. PubMed ID: 26256063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Selection of management tactics in treatment of giant prolactin-secreting pituitary adenomas].
    Astaf'eva LI; Kadashev BA; Kalinin PL; Kutin MA; Faĭzullaev RB; Sidneva IuG; Tenedieva VD; Tropinskaia OF
    Zh Vopr Neirokhir Im N N Burdenko; 2009; (2):23-8; discussion 28-9. PubMed ID: 19569545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on prolactinomas. Part 2: Treatment and management strategies.
    Wong A; Eloy JA; Couldwell WT; Liu JK
    J Clin Neurosci; 2015 Oct; 22(10):1568-74. PubMed ID: 26243714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macroprolactinemia in patients with prolactinomas: prevalence and clinical significance.
    Elenkova A; Genov N; Abadzhieva Z; Kirilov G; Vasilev V; Kalinov K; Zacharieva S
    Exp Clin Endocrinol Diabetes; 2013 Apr; 121(4):201-5. PubMed ID: 23595795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical practice. Prolactinomas.
    Klibanski A
    N Engl J Med; 2010 Apr; 362(13):1219-26. PubMed ID: 20357284
    [No Abstract]   [Full Text] [Related]  

  • 13. [Kinetics of prolactinemia after withdrawal of dopamine perfusion and during the administration of domperidone. Normal and hyperprolactinemic subjects (prolactinomas and suprahypophyseal lesions)].
    Bercovici JP; Khoury S; Tater D; Besson G; Caroff J
    Biomed Pharmacother; 1983; 37(5):222-7. PubMed ID: 6661508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between the methods of treatment for prolactinomas and the puerperal lactation.
    Ikegami H; Aono T; Koizumi K; Koike K; Fukui H; Tanizawa O
    Fertil Steril; 1987 May; 47(5):867-9. PubMed ID: 3569564
    [No Abstract]   [Full Text] [Related]  

  • 15. Giant invasive prolactinoma: a case report and review of nine further cases.
    Davis JR; Sheppard MC; Heath DA
    Q J Med; 1990 Mar; 74(275):227-38. PubMed ID: 2385731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.
    Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E
    Endocrine; 2017 Jan; 55(1):223-230. PubMed ID: 27688009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperprolactinemia and prolactinoma.
    Romijn JA
    Handb Clin Neurol; 2014; 124():185-95. PubMed ID: 25248588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical presentation, diagnostics and results of primary conservative treatment of large and giant prolactin-secreting pituitary adenomas].
    Astaf'eva LI; Kadashev BA; Kalinin PL; Kutin MA; Shkarubo AN; Fomichev DV; Faĭzullaev RB; Alekseev SN; Sidneva IuG; Tenedieva VD; Tropinskaia OF
    Zh Vopr Neirokhir Im N N Burdenko; 2008; (4):36-8; discussion 39. PubMed ID: 19230480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists.
    Neff LM; Weil M; Cole A; Hedges TR; Shucart W; Lawrence D; Zhu JJ; Tischler AS; Lechan RM
    Pituitary; 2007; 10(1):81-6. PubMed ID: 17285366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment.
    Ribeiro RS; Abucham J
    Eur J Endocrinol; 2009 Jul; 161(1):163-9. PubMed ID: 19359408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.